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Abstract: Along with hydration and urinary alkalinization, allopurinol has been the standard 
agent for the management of hyperuricemia in patients with a high tumor burden at risk of tumor 
lysis syn drome; however, this agent often fails to prevent and treat this compli cation effectively. 
Rasburicase (recombinant urate oxidase) has been shown to be effective in reducing uric acid and 
preventing uric acid accumulation in patients with hematologic malignancies with hyperuricemia 
or at high risk of developing it. Rasburicase acts at the end of the purine catabolic pathway and, 
unlike allopurinol, does not induce accumulation of xanthine or hypoxanthine. Its rapid onset 
of action and the ability to lower pre-existing elevated uric acid levels are the advantages of 
rasburicase over allopurinol. Rasburicase represents an effective alternative to allopurinol to 
promptly reduce uric acid levels, improve patient’s electrolyte status, and reverse renal insuf-
ﬁ  ciency. The drug, initially studied in pediatric patients with acute lympho blastic leukemia and 
aggressive non-Hodgkin lymphoma, seems to show comparable beneﬁ  t in adults with similar 
lymphoid malignancies or at high risk of tumor lysis syn  drome. Current and future trials will 
evaluate alternative doses and different schedules of rasburicase to maintain its efﬁ  cacy while 
reducing its cost. The review provides a comprehensive and detailed review of pathogenesis, 
laboratory, and clinical presentation of TLS together with clinical studies already performed 
both in pediatric and adult patients.
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Tumor lysis syndrome
Tumor lysis syndrome (TLS) is a severe and potentially life-threatening complication 
in patients with cancer; it may occur spontaneously (sTLS) or, more frequently, as 
a consequence of chemotherapy, radiotherapy, or immunotherapy (Flombaum 2000; 
Locatelli and Rossi 2005; Pession and Barbieri 2005; Riccio et al 2006). It was ﬁ  rst 
reported in 1929 in a group of adults with chronic leukemia (Bedrna 1929). Since 
then, several studies on TLS have been published, but its incidence is still not precisely 
deﬁ  ned (Flombaum 2000; Turtureanu-Hanganu 2002).
Recently Cairo and Bishop proposed a uniform deﬁ  nition of TLS, identifying 
a laboratory TLS (LTLS) and clinical TLS (CTLS). This stratiﬁ  cation of TLS may 
provide a useful tool to better identify appropriate therapy. LTLS is deﬁ  ned by the 
presence of at least 2 of the following laboratory data: hyperuricemia, hyperkalemia, 
hyperphosphatemia, and secondary hypocalcemia, deﬁ  ned as 25% change from base-
line or threshold value of serum level (Table 1). CTLS is deﬁ  ned by the presence of 
LTLS and one or more of the most signiﬁ  cant clinical complications related to TLS: 
renal insufﬁ  ciency, cardiac arrhythmias/sudden death, and seizure (Cairo and Bishop 
2004). Not surprisingly, laboratory evidence of TLS has been reported much more 
frequently than the symptomatic clinical syndrome (Jasek and Day 1994).Biologics: Targets & Therapy 2008:2(1) 130
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TLS may also be a spontaneous event (sTLS) occurring 
prior to chemotherapy initiation in a variety of malignancies, 
which has been reported mostly in patients with Burkitt’s 
lymphoma or mature B-cell leukemia, both characterized by 
a very rapid cell turnover rates (Alkhuja and Ulrich 2002). 
Identifying patients at risk of sTLS may have a signiﬁ  cant 
impact on outcome. In a recent study, sTLS in patients with 
malignancies is deﬁ  ned by presence of pretreatment hyper-
uricemic acute renal failure (ARF), ratio of urinary uric acid 
to creatinine (Cr)  1.0, and signiﬁ  cantly elevated lactate 
dehydrogenase ( 500 units/L); TLS was demonstrated to 
occur in 1.08% of 926 patients with ARF (Hsu et al 2004). 
A possible distinction between spontaneous tumor lysis and 
TLS occurring after therapy is the lack of hyperphosphatemia 
in the spontaneous form.
Factors predisposing the development of TLS include a 
high tumor growth fraction, as in Burkitt’s lymphoma, lym-
phoblastic lymphoma, B-cell acute lymphoblastic leukemia 
(B-ALL), and T-cell ALL with hyperleukocytosis and/or 
extensive extramedullary disease; cases of TLS in patients 
with solid tumor have also been extensively reported in 
tumors with high sensitivity to chemotherapy and large tumor 
burden (Feld et al 2000; Habib and Saliba 2002; Stark et al 
1987; Tomlinson and Solberg 1984). In addition elevated 
lactate dehydrogenase (LDH) serum levels, and decreased 
urinary ﬂ  ow confer higher risk of TLS onset (Cairo and 
Bishop 2004). Although TLS occurs at all ages, advanced age 
leading to impaired renal function may predispose patients to 
clinically signiﬁ  cant TLS. Neither racial nor sex predilection 
has been reported.
Cytotoxic therapy or highly proliferative tumor is the 
primary origin of TLS. Some chemotherapeutic agents such 
as cytosine arabinoside, etoposide, cisplatin, and intrathecal 
methotrexate have been more frequently implicated in causing 
TLS (Locatelli and Rossi 2005), although no one regimen 
or drug may be speciﬁ  cally indicated as carrying a higher 
likelihood of causing TLS. Thus host characteristics remain key 
factors in TLS development. TLS has been also observed after 
infusion of monoclonal antibodies (rituximab, gemtuzumab-
ozogamicin), high dose-corticosteroids, radiotherapy (total 
body irradiation), interferon, thalidomide, hydroxyurea, 
imatinib, and fludarabine. Anecdotal cases of TLS 
after hormonal therapy for breast carcinoma and prostate 
cancer have also been reported. There is no consensus to 
date for stratiﬁ  cation of patients at high risk of TLS, but 
data can be drawn from most of the reports available to 
suggest some useful criteria (for adults and children), as 
indicated in Table 2. TLS onset occurs early in patients 
with high risk hematological neoplasm (within 1–5 days of 
therapy initiation), due to peculiar biological characteristics 
of malignant lymphoid cells (high proliferative rate, 
synchronous kinetics); thus careful monitoring of laboratory 
parameters and supportive therapies are the most important 
measures to prevent or successfully manage TLS. In contrast, 
TLS occurring in solid tumor patients usually shows a later 
onset than in hematological malignancies. This difference 
may be related to more synchronous kinetics of lympho-
myeloproliferative disorders cells than solid tumor cell. TLS is 
a rare but extremely severe complication of treatment of adult 
solid tumors. TLS toxicity-related death rate is surprisingly 
higher in this subset of patients, in which nearly 35% of all 
cases developing clinical TLS die. The reasons might lie in 
the delayed initiation of prophylactic measures to prevent 
or treat TLS in patients with solid tumor, and generally less 
close monitoring during and after therapy initiation. Virtually 
all tumor types have been reported including some diseases 
relatively or poorly responsive to chemotherapy (melanoma, 
colorectal, gastric, vulvar, hepatocellular carcinoma), but the 
majority of reported cases of TLS were in patients with cancer 
known to be highly or very highly sensitive to chemotherapy 
such as small cell lung cancer and germ cell carcinoma 
(Sparano et al 1990; Coutinho et al 1997; Habib and Saliba 
2002; Annemans et al 2003).
In a recent paper Wossmann et al analyzed the incidence 
and complications of TLS in 1791 children with non-Hodgkin 
lymphoma (NHL) enrolled in the two subsequent multicenter 
studies NHL-BFM 90 and 95. Out of this group, 78 (4.4%) 
developed a TLS and 42 (2.3%) oligoanuria. Patients with 
Burkitt’s lymphoma or B-ALL had a higher incidence of 
TLS (8.4%) and anuria (4.4%); in particular, patients with 
B-ALL had the highest risk to develop a TLS (26.4%) and 
anuria (14.1%). Of the 790 patients with Burkitt ’s lymphoma 
or B-ALL, tumor burden, as indicated by the plasma level of 
LDH, was the main predictor for the development of both TLS 
and anuria. The TLS incidence was 1.2%, 12.7%, and 19.1% 
Table I Laboratory criteria of tumor lysis syndrome 
Uric acid  Increase of more than 25% from baseline if available or
 Values   476 μmol/L 8 mg/dL
Potassium  Increase of more than 25% from baseline if available or
 Values   6.0 mmol/L 6 mEq/dL
Phosphorus  Increase of more than 25% from baseline if available or
 Values   1.45 mmol/L 4.5 mg/dL for adults patients
 Values   2.1 mmol/L 6.5 mg/dL for pediatric patients
Calcium  Decrease of more than 25% from baseline if available
 or  Values   1.75 mmol/L 7 mg/dL
Modiﬁ  ed from Cairo and Bishop (2004).Biologics: Targets & Therapy 2008:2(1) 131
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for patients with a LDH level of  500 U/L, 500–1000 U/L, 
and  1000 U/L respectively. The incidence of TLS in patients 
with T-lymphoblastic lymphoma and other B-cell NHL was 
below 2% and anuria occurred in less than 1% (Wossmann 
et al 2003). TLS is rare in acute myeloid leukemia (AML) 
despite the high blood cell count. TLS has also been docu-
mented in childhood solid tumors such as neuroblastoma, 
medulloblastoma, and germ cell tumors. TLS has also been 
observed, although rarely, in children treated with agents 
without a potent cytotoxic action such as interferon alfa, 
IL-2, STI-571.
Pathogenesis of TLS
Pathogenesis of TLS is complex and derives from rapid 
turnover and/or large destruction of tumor cells, resulting 
in a synchronous release of intracellular ions and metabolic 
byproducts into the circulation. When this massive discharge 
cannot be compensated for by cellular buffering and renal 
elimination mechanisms, numerous life-threatening metabolic 
derangements occur such as hyperuricemia, hyperkalemia, 
hypocalcemia hyperphosphatemia, metabolic acidosis, and 
acute renal insufﬁ  ciency (Figure 1).
Hyperuricemia
The increase in uric acid concentration in plasma is constantly 
present in patients with TLS; hyperuricemia may be already 
present at time of diagnosis or develop 2–3 days after initia-
tion of anti-cancer treatment. A high nucleic acid content and 
a very active purine metabolism are characteristic of tumor 
cells. The metabolism of nucleic acid purines (adenosine 
and guanine) occurs in the liver, where purines are reduced 
to xanthine, and then degraded to uric acid by the enzyme 
xanthine oxidase. Thus the destruction of tumor cells yields a 
large amount of uric acid. Some animal species are known to 
have the enzyme urate oxidase which catalyzes degradation 
of uric acid to allantoin, a much more soluble compound. 
Unfortunately during evolution humans and non-human 
primates have lost this catabolic pathway due to a nonsense 
mutation of this enzyme (Yeldandi et al 1991). The presence 
of hyperuricemia may induce the crystallization of uric acid 
Table 2 Risk stratiﬁ  cation deﬁ  nition and criteria 
At high risk of developing tumor lysis syndrome are those 
patients who carry at least one of the following co-morbidities, 
disease-related or therapy-related factors 
 Pediatric  patients
Co-morbidities  - Renal impairment at diagnosis appear to be 
    the only relevant co-morbidity in children
  - Kidney tumor involvement at onset
  - Hyperuricemia UA   8 mg/dL
Disease-related  - Tumors with high proliferative rate
factors  - Bulky solid tumor especially if massive liver 
   metastasis
  - Lympho-myeloproliferative disorders with  
    large tumor burden as WBC   50,000/mm3 or
   LDH    2 times normal level
  - High grade lymphomas 
    particularly Burkitt’s lymphoma and T-cell NHL
  - B-cell and T-cell acute lymphoblastic leukemias
Treatment-related  - Intensive cytoreductive chemotherapy in 
factors   hematologic  malignancies
 Adult  patients
Co-morbidities  - Dehydratation
  - Hyponatriemia
  - Pre-existing renal impairment 
    including tumor inﬁ  ltration that reduce renal
   function
  - Obstructive uropathy
  - Hyperuricemia UA   10 mg/dL
Disease-related  - Tumors with high proliferative rate
factors  - Bulky solid tumor especially if massive 
   liver  metastasis
  - Lympho-myeloproliferative disorders with  
    large tumor burden such as  50,000/mm3 or 
   LDH    2 times normal level
  - Advanced germ cell lung cancer
  - High grade lymphomas particularly Burkitt’s 
   lymphoma,  a  T-cell  NHL
  - B-cell acute lymphoblastic leukemias
Treatment-related  - Intensive cytoreductive chemotherapy in 
factors   hematologic  malignancies
Abbreviations: LDH, lactate dehydrogenase; NHL, non-Hodgkin lymphoma; UA, uric acid; 
WBC, white blood cell.
Figure 1 Purine catabolic pathway and site of action of allopurinol and rasburicase.
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in the renal collecting ducts and in the deep cortical and 
medullar vessels, leading to the development of acute renal 
failure. The crystallization of uric acid is also enhanced 
by hemoconcentration and decreased tubular ﬂ  ow rate; 
moreover, a reduced solubility of uric acid is enhanced by 
decreased pH of renal tubule.
Hyperkalemia
Hyperkalemia results from massive cellular degradation and 
efﬂ  ux of potassium, and may represent a life-threatening 
complication in patients with TLS. The presence of renal 
insufﬁ  ciency and metabolic acidosis may worsen hyperkale-
mia, overwhelming the potassium excretory capacity of the 
kidney. Clinical manifestations of hyperkalemia are nausea, 
vomiting, and diarrhea. More specifically hyperkalemia 
induces cardiac and neuromuscular abnormalities such as elec-
trocardiographic (ECG) changes and life-threatening cardiac 
arrhythmia, including asystole. When hyperkalemia is severe 
it is always associated with ECG alterations such as peaked 
T waves, ﬂ  attened P waves, prolonged PR interval, widened 
QRS complexes, deep S waves and sine waves, ventricular 
tachycardia or ﬁ  brillation, syncope, and possible sudden death. 
These ECG abnormalities must be promptly diagnosed and 
treated through stabilization of the myocardial cell membrane, 
intracellular shift of potassium, and reduction of total ion load, 
in order to reduce the risk of fatal ventricular arrhythmia. 
Neuromuscular signs of hyperkalemia includes muscle 
weakness, paresthesias, and cramps (Parham et al 2006).
Hyperphosphatemia and hypocalcemia
As with the other laboratory abnormalities, hyperphosphate-
mia is the consequence of rapid cell lysis; it develops quickly, 
24–48 hours after anti-cancer treatment. In this regard, it has 
been estimated that the phosphorus content of lymphoblasts is 
3–4 times that of normal lymphocytes (Barton 1989; Locatelli 
and Rossi 2005). In order to reduce phosphorus concentration 
the kidney decreases tubular re-adsorption and increases 
excretion. Hyperphosphatemia may be also induced by acute 
renal insufﬁ  ciency. Severe hyperphosphatemia may be associ-
ated with nausea and vomiting, lethargy, and seizure.
Hypocalcemia usually occurs together with hyperphos-
phatemia, due to precipitation of calcium phosphate in soft 
tissues including kidney, where it produces nephrocalcinosis, 
which may occur when in vivo concentration of calcium 
phosphate salts exceeds the solubility product of 4.6 mmol/L. 
Moreover, deposits of calcium in the renal tubules elicits 
an inﬂ  ammatory response exacerbating the risk of ARF 
(Ribeiro and Pui 2003; Locatelli and Rossi 2005). Calcium 
phosphate is less soluble at an alkaline pH, which can exac-
erbate the risk of its deposit. Iatrogenic urine alkalinization 
in patients presenting TLS with hyperphosphatemia and/or 
hypocalcemia may be associated with an increased risk of 
nephrocalcinosis, and thus it must be avoided especially in 
patients whose calcium × phosphate product exceeds the 
solubility limit. When hypocalcemia is severe it may be 
associated with critical clinical manifestation such as muscle 
cramps, paresthesias, tetany and seizures, cardiac ECG 
abnormalities such as lengthening of QT interval, ventricular 
arrythmias, and hypotension. Treatment of asymptomatic 
hypocalcemia is not generally recommended in patients with 
TLS due to the higher risk calcium phosphate precipitation 
and consequently nephrocalcinosis.
Metabolic acidosis
Metabolic acidosis may develop concomitant with ARF 
and because of liberation of a large amount of endogenous 
intracellular metabolites from cellular catabolism. Acidosis 
induces a decrease in bicarbonate concentration and an high 
anion gap which may worsen the imbalance of electrolytes in 
patients with TLS, such as uric acid solubility and impaired 
intracellular uptake of potassium (Filler 2001).
Acute renal failure
As mentioned previously the kidney is the primary organ 
involved in clearance of uric acid, potassium, and phosphate; 
thus, it is expected that abnormalities of renal function, charac-
teristic of TLS, predispose patients to worsening of metabolic 
derangements typical of this syndrome. Renal dysfunction 
can be severe in patients with TLS, but in the majority of 
cases, if diagnosed in a timely manner and promptly treated 
with supportive measures, it is reversible. The major cause 
of oliguric acute renal failure is the nephropathy mediated by 
mechanical obstruction by uric acid crystals (Hsu and Huang 
2004). Intra-tubular obstruction causes azotemia/oliguria in 
acute uric acid nephropathy, and vascular obstruction can 
contribute to ﬁ  ltration failure. Uric acid crystallization in the 
distal tubules/cortical collecting ducts is not the only factor 
operating in the mechanical obstruction of kidney. In fact, as 
mentioned above, nephrocalcinosis signiﬁ  cantly contributes 
to renal injury in acute TLS.
Moreover, precipitation of xanthine, less soluble in urine 
than uric acid, or other purine metabolites increased by use 
of allopurinol, may be rarely involved in the development 
of ARF (LaRosa et al 2007).
Oliguria due to acute uric acid nephropathy rapidly 
responds to hemodialysis (HD) often with a re-start of Biologics: Targets & Therapy 2008:2(1) 133
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diuresis as the plasma uric acid level falls to 10 mg/dL. 
Frequently the development of ARF in the cancer patient is 
enhanced by several factors that may induce a decrease in 
glomerular ﬁ  ltration, such as ﬂ  uid depletion because of poor 
intake, fever and vomiting, and presence of renal dysfunc-
tions due to tumor inﬁ  ltration.
Drugs for treatment 
of hyperuricemia in TLS
Allopurinol
Allopurinol has been used in the US since 1964. Allopurinol 
is a structural isomer of hypoxanthine and acts to inhibit 
xanthine oxidase. This enzyme is responsible for the suc-
cessive oxidation of hypoxanthine and xanthine resulting 
in the production of uric acid, the end-product of human 
purine metabolism. In addition to blocking uric acid pro-
duction, inhibition of xanthine oxidase increases plasma 
concentrations of the uric acid precursors hypoxanthine 
and xan  thine (Figure 1), which are converted to closely 
related purine ribotides adenosine and guanosine monophos-
phates. Increased levels of these ribotides causes feedback 
inhibition of amidophosphoribosyl transferase, the ﬁ  rst and 
rate-limiting enzyme of purine biosynthesis (Pea 2005).
Allopurinol therefore decreases both uric acid formation 
and purine synthesis. Patients with or at high risk of tumor 
lysis still need to excrete the pre-existing uric acid that is not 
targeted by allopurinol.
Allopurinol is rapidly metabolized by its target, xan-
thine oxidase, to its active metabolite oxypurinol, which is 
also an inhibitor of xanthine oxidase. Allopurinol is almost 
completely metabolized to oxypurinol within 2 hours of oral 
administration, whereas oxypurinol is slowly excreted by the 
kidney over 18–30 hours (Holdsworth and Nguyen 2003).
Although allopurinol is effective in preventing further syn-
thesis of uric acid, it has a limitation not being able to degrade the 
uric acid already present. Allopurinol is usually given together 
with alkaline hyperdiuresis to clear renal acid crystals, a process 
that takes up to 7–10 days; therefore its use during severe hyper-
uricemia may possibly imply a delay in starting chemotherapy. 
In fact chemotherapy should be instituted carefully in patients 
with hyperuricemia for at least 1–2 days after allopurinol therapy 
is initiated to allow uric acid to be excreted. Moreover, since 
xanthine and hypoxanthine are less soluble than uric acid, their 
accumulation may be toxic and may precipitate in a manner 
similar to that of uric acid, also causing renal failure In children 
with ALL receiving allopurinol, xanthine may predispose them 
to renal medullary sludging, which has been implicated as a 
possible mechanism for ARF (Andreoli et al 1986).
Side effects of allopurinol are rare, though signiﬁ  cant 
when they occur; skin reactions are the most frequent adverse 
event reported, and antibiotics may cause an increase in these 
rashes. Serious skin reactions such as exfoliative rashes may 
occur as part of generalized hypersensitivity consisting of 
fever, skin rash, eosinophilia, hepatitis, worsening renal 
function and may result in toxic epidermal necrolysis or in 
Stevens-Johnson syndrome (Andreoli et al 1986). Hepatic 
complications may also occur in as  sociation with the hyper-
sensitivity syndrome. The dose of al  lopurinol should be 
reduced in patients with impaired renal function.
Enhanced bone marrow suppression has been reported 
when allopurinol is used with cyclophosphamide and other 
cytotoxic agents (Cheson and Dutcher 2005). Allopurinol 
also inhibits the degradation of 6-mercaptopurine and 
azathioprine, thereby increasing their toxicity.
Recombinant urate oxidase
Urate oxidase is an enzyme involved in purine metabolism and 
is responsible for the oxidation of uric acid to allantoin, which 
has been shown to be 5–10 times more soluble in urine than uric 
acid. This enzyme is found in most mammals, but not in humans, 
because of a nonsense mutation in the coding region of the gene 
during hominoid evolution (Friedman et al 1985; Yeldandi et al 
1991). Uric acid is the end product of purine metabolism in 
humans (Figure 2) (Cammalleri and Malaguarnera 2007).
The ﬁ  rst molecule of this type, synthesized in 1968 
and introduced in France and in Italy in 1975 and 1982, 
respectively, was a non-recombinant urate oxidase. It was 
a natural uricase, obtained from Aspergillus ﬂ  avus cultures 
(UricozymeTM), indicated to prevent and treat hyperuricemia 
occurring during chemotherapy (Navolanic et al 2003) 
(Masera et al 1982).
The genetic absence of this molecule in humans and its 
proteic nature together with poor accuracy in puriﬁ  cation 
and a slow production process confer a high immunogenicity 
to the compound, leading to elevated rate of hypersensivity 
reactions; 5% of patients developed reactions such as rashes, 
urticaria, angioedema, and bronchospasm within few minutes 
of infusion during the ﬁ  rst administration (Pui et al 1997).
In 1996, using the recombinant DNA technique, another 
molecule was obtained from a genetically modiﬁ  ed Saccha-
romyces cerevisiae strain that expresses urate oxidase cDNA, 
cloned from a strain of A. ﬂ  avus (Leplatois et al 1992). This 
technology enabled production of a molecule of urate oxi-
dase (rasburicase) characterized by higher purity and higher 
activity in compared with non-recombinant urate oxidase 
(Bayol et al 2002).Biologics: Targets & Therapy 2008:2(1) 134
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Generally, rasburicase maintains the same mechanism 
of action as the non-recombinant form of urate oxidase, 
but simply shows a signiﬁ  cantly lower reaction rate. Even 
if allo-antibodies are documented in vivo in some reports, 
a lower immunogenicity of the compound is evident con-
sidering that other studies did not identify allo-antibodies 
even after several days of treatment (Goldman et al 2001). 
Pegylation tecnique has been proposed to prolong the half-
life of rasburicase. Rasburicase use for treatment of other 
hyperuricemic conditions such as chronic gout is difﬁ  cult, 
essentially because this drug is immunogenic and requires 
a daily administration.
Pharmacokinetics of rasburicase
Information about pharmacokinetics is derived from the 
use of rasburicase in children and young adults. Few data 
are available in adults and the elderly (Ueng 2005). The 
pharmacokinetics of rasburicase were studied in 40 patients 
with or at high risk of hyperuricemia enrolled in 2 clinical 
trials (Mahmoud et al 1998; Pui et al 2001a).
Rasburicase 0.15 or 0.2 mg/kg was administered 
intravenously over 30 minutes for 5–7 days. The mean AUC0–24 
at 0.15 mg/kg was 32.9 mg/L/h on day 1 and 34.4 mg/L/h 
on day 5. The AUC0–24 was 45.2 mg/L/h on day 1 and 47.3 
mg/L/h on day 5 for the 0.2 mg/kg dose (Pui et al 2001a). 
At either dosage level, there was no signiﬁ  cant difference 
between the mean AUC0–24 on days 1 and 5 indicating that 
rasburicase does not accumulate in the plasma. The mean peak 
concentrations on day 5 were 3.36 and 4.5 mg/L with 0.15 and 
0.2 mg/kg, respectively. At a dose of 0.15 and 0.2 mg/kg, the 
mean half-life values were between 16–17.4 and 21.1 hours 
respectively For an half-life of 19 hours, rasburicase has to 
be administered once a day. Even after 5 days of treatment, a 
consistent accumulation has not been reported (Pui et al 2001a; 
Mahmoud et al 1998).
In vitro interaction studies show that rasburicase does not 
interact with allopurinol, cytarabine, methylprednisolone, 
methotrexate, mercaptopurine, thioguanine, etoposide, dau-
norubicin, cyclophosphamide, or vincristine (Pea 2005).
Association between rasburicase and allopurinol should 
be avoided, because the latter may reduce the effect of 
rasburicase owing to its inhibition of xanthine oxidase and 
consequent reduced uric acid concentration (Jeha and Pui 
2005). As other protein rasburicase catabolism occurs by 
peptide hydrolysis without involvement of liver function, 
the cytochrome P450 is not induced or inhibited. For this 
reason coexistent hepatic pathology does not necessitate any 
adjustment of dosage (Navolanic et al 2003). Its clearance 
does not depend on renal function.
Because rasburicase causes enzymatic degradation of uric 
acid within blood/plasma/serum samples at room temperature, 
a falsely low plasma uric acid assay reading may be produced. 
Therefore, proper sample handling must be followed to 
avoid ex vivo uric acid degradation. Blood must be collected 
into pre-chilled tubes containing heparin and immediately 
immersed in an iced water bath. The plasma samples must be 
prepared by centrifugation in a pre-cooled centrifuge (4 °C) 
and maintained in an iced water bath and analyzed for uric 
acid within 4 hours of collection (Lim et al 2003).
Safety proﬁ  le
Overall, rasburicase is well tolerated. The most common 
adverse event (AE) is skin rash, which was reported with an 
incidence of 2.5% in 196 patients evaluated in 3 trials. Skin 
rash was of grade I severity in 4 patients and was transient 
and localized in 1 patient. In another clinical trial evaluating 
131 patients who were  20 years of age, 1 (0.8%) severe AE 
(SAE) was registered: a 13-year-old girl with B-cell precursor 
ALL and pneumonia developed bronchospasm and hypox-
emia 3 hours after the ﬁ  rst dose of rasburicase and required 
treatment with oxygen and bronchodilator, and recovered 3 
days later (Pui et al 2001a). Other AE included mild nausea 
Figure 2 Pathogenesis of tumor lysis syndrome.
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and vomiting. Other adverse reactions are in order of decreas-
ing incidence: fever (6.8%), neutropenia with fever (4%), 
respiratory distress (3%), sepsis (3%), neutropenia (2%), 
mucositis (2%), nausea (1.7%), vomiting (1.4%), headache 
(0.9%), diarrhea (0.9%), and abdominal pain (Cammalleri 
and Malaguarnera 2007).
Since patients with glucose-6-phosphate dehydrogenase 
(G6PD) deﬁ  ciency are unable to break down hydrogen per-
oxide, a product of the urate oxidase reaction, urate oxidase 
is contraindicated in these patients for the risk of hemolysis 
(Browning and Kruse 2005).
However, hemolysis may occur in patients without G6PD 
deﬁ  ciency. Rasburicase was discontinued because of hemo-
lysis in an 11-year-old boy with pre-B precursor ALL and no 
evidence of G6PD deﬁ  ciency (Goldman et al 2001).
The Food and Drug Administration has issued a Black 
Box Warning for rasburicase for hemolysis due to G6PD, 
hypersensitivity reactions including anaphylaxis, methemo-
globinemia, and interference with uric acid measurements.
The formation of antibodies to rasburicase raises the 
concern that the administration of subsequent doses would 
increase the risk of hypersensitivity and decrease its efﬁ  -
cacy. Antibodies against rasburicase or a part of it that is 
recognized by the immune system (epitopes) were detected 
in between 0% (Goldman et al 2001) and 14% of patients 
(Pui et al 2001b).
Repeated use of rasburicase increases risk of hypersensi-
tivity reactions: skin rashes (1.4%), urticaria, bronchospasm 
( 1%), dyspnea, hypoxemia, and anaphylactic shock ( 1%) 
(Jeha and Pui 2005). In these conditions, patients should be 
monitored during treatment and the drugs should be dis-
continued immediately, in association with an appropriate 
anti-allergic supportive therapy. Caution should be used in 
patients with a history of allergy. A re-treatment has the same 
efﬁ  cacy but titers of antirasburicase antibodies (10%–20%) 
could increase, even though most of them are not neutralizing 
(Pui 2002).
Antibodies develop about 1–6 weeks after administra-
tion. The detection of antibodies is highly dependent on 
the sensitivity and speciﬁ  city of the assay adopted for their 
determination and inﬂ  uenced by other factors such as serum 
sampling, timing and methodology, concomitant medica-
tions, and underlying disease. The presence of antibodies 
did not correlate with the clinical status of the patients or the 
occurrence of SAE/AE. The need for a re-treatment is rarer 
in neoplastic relapse, because this condition is more resistant 
to chemotherapy and so at lower risk of TLS development 
(Pui et al 2001b).
Dosing and administration
Rasburicase recommended dose is 0.20 mg/kg/day diluted 
in 50 mL of sodium chloride solution (0.9%), adminis-
tered intravenously for 30 minutes, daily for 3–5 days. 
Administration beyond 5 days is not recommended by the 
manufacturer, but a shorter period and/or lower dosage 
has been evaluated in a number of studies (Hummel et al 
2005). A single dose of rasburicase, at low dosage, has 
shown a rapid reduction of hyperuricemia (Liu et al 2005; 
Hutcherson et al 2006; McDonnell et al 2006; Triﬁ  lio et al 
2006). Contemporary use of alkalinization, hydration, and 
rasburicase at 0.10 mg/kg for 3–5 days maintains the same 
efﬁ  cacy (Tarella et al 2005). In a recent review Cammalleri 
and Malaguarnera state that it may be more favorable to 
adjust the dose of rasburicase, according to clinical condi-
tion, type of malignancy, and chemotherapy adopted, in 
order to reduce the total cost of the patient’s management 
and to reduce the risk of antibody development (Cammalleri 
and Malaguarnera 2007). Administration of more than one 
course of rasburicase is feasible, even if not recommended, 
because of the possible higher rate of reaction and/or anti-
bodies mediated by drug inactivation.
Chemotherapy may begin 4–24 hours after completion 
of the ﬁ  rst dose of rasburicase. Each vial of rasburicase must 
be reconstituted in the diluent provided by the producer, then 
diluted in 50 mL of preservative-free NaCl 0.9% and infused 
over 30 minutes within 24 hours of reconstitution.
Monitoring
Laboratory monitoring parameters should include serum uric 
acid, potassium, phosphate, calcium, and creatinine. Patients 
should be observed for allergic reactions. Symptoms may 
include urticaria, chest pain, and/or hypotension. Patients 
should also be monitored for any signs and symptoms of 
hemolysis or methemoglobinemia.
Therapeutic issues
Rasburicase was approved in the EU under the name 
Fasturtec® in February 2001 and in the US under the name 
of Elitek® in July 2002 with slightly different indications: 
for the treatment and prevention of chemotherapy-induced 
hyperuricemia and ARF in patients with hematological 
malignancies at risk of TLS, and for the initial manage-
ment of plasma uric acid levels in pediatric patients with 
leukemia, lymphoma, and solid tumor malignancies who 
are receiving anti-cancer therapy expected to result in 
tumor lysis and subsequent elevation of plasma uric acid, 
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Clinical studies on rasburicase
The clinical development of rasburicase has been conducted 
primarily in Europe, the US, and Canada, and studies have 
accrued on more than 1200 subjects. Studies to date have 
included a phase I clinical trial, two phase II studies, a phase 
III comparative trial with allopurinol, and a safety study 
(Mahmoud et al 1998; Goldman et al 2001; Pui et al 2001a). 
In addition, compassionate-use trials in selected patients were 
conducted in Europe and North America prior to market 
availability (Pui et al 2001a; Patte et al 2002; Pession and 
Barbieri 2005).
Phase I trials
Rasburicase was ﬁ  rst evaluated in single daily dose with 
dose escalation administered to 28 healthy male volunteers 
enrolled in a phase I, single-center, open-label trial 
(Mahmoud et al 1998). Four volunteers at each dosage level 
received either 0.05, 0.1, 0.15, or 0.2 mg/kg intravenously 
in the ﬁ  rst phase of the trial. A rapid dose-related decline 
in uric acid was observed: at 8 hours following a single IV 
infusion of rasburicase, uric acid levels decreased by 78.4%, 
84.3%, 91.9%, and 96.0% with doses of 0.05, 0.10, 0.15 
mg/kg, and 0.20 mg/kg, respectively. In the second phase, 
a daily dose of 0.1, 0.15, or 0.2 mg/kg was administered 
intravenously to 4 subjects at each dosage level for 5 
consecutive days, conﬁ  rming the rapid dose-related efﬁ  cacy 
of the drug.
Phase II trials
In another study evaluating the efﬁ  cacy and safety of rasbu-
ricase in 107 patients with NHL, ALL, or AML, rasburicase 
0.15 mg/kg/d was given for 5–7 days (Mahmoud et al 1998). 
Efﬁ  cacy was determined by control of plasma uric acid 
concentration, with an upper limit of 6.5 mg/dL in patients 
 13 years of age or 7.5 mg/dL in patients  13 years old, and 
prevention of renal complications. Uric acid concentrations 
were reduced by at least 25% 4 hours after the ﬁ  rst dose in 
94% and were below the upper limit (6.5 mg/dL in patients 
 13 years of age or 7.5 mg/dL in patients  13 years old) by 
48 hours in 99% of treated patients. Twenty-three patients 
experienced TLS, but none required dialysis. Approximately 
7% of patients developed antibodies with inhibiting activity. 
Overall, rasburicase was well tolerated, with only 2 patients 
developing grade I rashes.
Pui et al conducted a pivotal multicenter, open-label, 
phase II clinical trial that enrolled 131 patients aged 
 20 years at high risk for or with hyperuricemia as a 
result of B mature or B-cell precursor or T-cell ALL, stage 
III or IV Burkitt’s lymphoma, or AML. All patients had 
either laboratory evidence of hyperuricemia (deﬁ  ned as 
a plasma uric acid concentration of  8 mg/dL) or were 
consid  ered to be at high risk for hyperuricemia because of 
a large tumor burden. The study was divided into 2 phases: 
a dose-validation phase to select the optimally effective 
dose followed by an accrual phase, which veriﬁ  ed the 
effectiveness of the dose chosen. The primary objectives 
of the study were to assess the efﬁ  cacy, safety, and toler-
ability of rasbu ricase in controlling and normalizing malig-
nancy-related or tumor lysis-related hyperuricemia. The 
secondary objective was to determine the pharma cokinetics 
of rasburicase in this population. The starting dose was 
0.15 mg/kg (n = 12) and was increased by increments of 
0.05 mg/kg up to 0.20 mg/kg/d (n = 119), deﬁ  ned as the 
dose that corrected hyperuricemia (plasma uric acid  6.5 
mg/dL in patients  13 years old or  7.5 mg/dL in older 
patients) within 48 ± 2 hours (mean ± SD) after the start of 
treatment and prevented hyperuricemia for up to 24 hours 
after treatment in 14 consecutive patients. The dose was 
administered daily for 5–7 days, and the frequency could 
be increased to every 12 hours during the ﬁ  rst 48 hours. 
The patient population was followed for up to 66 days. 
Around 50% of patients presented with hyperuricemia at 
onset. Overall, rasburicase produced a rapid and consistent 
decrease in plasma uric acid concentration in all patients 
treated with either dose. The median plasma uric acid 
concentration at diagnosis was 5.7 mg/dL (range 2.6–33.8) 
and declined to a median of 0.5 mg/dL (range 0.08–15.4) 
4 hours after the ﬁ  rst rasburicase treatment (p   0.0001) 
both in 65 patients with hyperuricemia and in 66 patients 
without hyperuricemia at presentation. The median plasma 
uric acid remained at or near 0.5 mg/dL in both groups 
throughout the treatment course. Serum creatinine concen-
trations decreased signiﬁ  cantly after 1 day of treatment in 
both groups and returned to normal range in all patients by 
day 6. None of the patients required dialysis. Serum phos-
phorus concentrations, monitored daily, did not decrease 
until day 4 of treatment and returned to normal 48 hours 
after the end of treatment; meanwhile serum potassium 
concentrations remained stable throughout the treatment 
course. Rasburicase was well tolerated and only minimal 
toxicity was reported. The investigators suggested that 
rasburicase 0.2 mg/kg be used in future studies because 1 
patient with stage III non-cleaved-cell NHL and an initial 
uric acid concentration of 21.1 mg/dL who received ras-
buricase 0.15 mg/kg had a transient increase in uric acid. 
In addition, rasburicase 0.2 mg/kg produced a higher rate Biologics: Targets & Therapy 2008:2(1) 137
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of urinary excretion of allantoin; and no additional adverse 
effects were observed (Pui et al 2001a).
Phase III trials
Goldman et al reported an open-label, multicenter, random-
ized phase III trial conducted in the US between November 
1996 and December 1997, comparing allopurinol with 
rasburicase for prophylaxis and treatment of hyperuricemia 
in children with leukemia or lymphoma at high risk for 
TLS. Patients were stratiﬁ  ed by the presence or absence of 
hyperuricemia and by disease being eligible for the study if 
they had Murphy stage III or IV NHL, ALL with a periph-
eral white blood cell count  25 × 103/mm3 at presentation, 
or any childhood lymphoma or leukemia with a uric acid 
level  8 mg/dL at the time of study entry. Out of the 52 
patients were enrolled: 20 patients with leukemia and 7 with 
lymphoma were randomized to receive for at least 5–7 days 
rasburicase (0.2 mg/kg intravenously administered over 30 
minutes daily); 19 patients with leukemia and 6 with lym-
phoma were randomized to receive oral allopurinol (100 
mg/m2 per dose or 3.3 mg/kg per dose administered every 
8 hours). All patients received hyper-hydration of approxi-
mately 3 L/m2 daily and intravenous sodium bicarbonate 
20–40 mEq/L. Plasma uric acid was measured immediately 
before administration and at hours 4 and 12, then every 
12 hours through 96 hours. The primary objective was to 
compare the decrease in mean plasma uric acid levels induced 
by the two drugs during the ﬁ  rst 5 days of chemotherapy. 
The secondary objective was to compare the reduction of 
uric acid levels at 4 hours after administration of rasburicase 
prior to the delivery of chemotherapy. In the rasburicase 
group, 10 of the 27 pa  tients were hyperuricemic prior to 
treatment; in the allopurinol group, 9 of the 25 patients were 
hyperuricemic at baseline. The two drugs were compared by 
measuring the mean uric acid AUC (area under the curve) 
from baseline to 96 hours AUC0–96. In the intent-to-treat 
analysis, the mean uric acid AUC0–96 was 128 ± 70 mg/dL/h 
for the rasburicase group and 329 ± 129 mg/dL/h for the 
allopurinol group (p   0.0001). Rasburicase-treated patients 
experienced a 2.6-fold lower exposure to plasma uric acid 
during the ﬁ  rst 96 hours of therapy. Twenty-four hours after 
the ﬁ  rst dose, patients randomized to receive rasburicase 
achieved a reduction in initial plasma uric acid levels of 
86% compared with 12% for allopurinol (p   0.0001). 
Rasburicase therapy prevented further increases in serum 
creatinine levels, although the study size was too small to 
detect a signiﬁ  cant difference in the incidence of ARF or in 
the number of patients requiring renal supportive measures; 
a single patient on the allopurinol arm, compared with none 
treated with rasburicase, required dialysis. No anaphylactic 
events occurred and no antibodies were detected at day 14 in 
the patients treated with rasburicase (Goldman et al 2001).
Retrospectives and compassionate 
studies
Patte et al conducted a retrospective review of 410 patients 
with advanced stage B-cell NHL and L3 ALL at the initia-
tion of chemotherapy with the LMB 89 protocol, which has 
been followed in France since 1981. It consisted of 1 week 
of a cytoreductive low-dose regimen of chemotherapy con-
comitant with non-recombi  nant urate oxidase (Uricozyme, 
which is not widely available in the US) administered as an 
IV for 30 minutes for 5 days. Intensive chemother  apy was 
then initiated on day 8. Only 5% of patients experienced 
severe meta bolic problems after the initiation of therapy, and 
only 1.7% required dialysis as a result of TLS. The authors 
compared their data with published re  sults from UKCCSG 
and POG protocols, which include essentially the same che-
motherapy with out the administration of urate oxidase. They 
noted that 16% of patients on the UKCCSG pro  tocol and 
23% of patients on the POG protocol required dialysis. This 
retrospective comparison suggested that treatment with urate 
oxidase may reduce metabolic and renal complications and 
the need for dialysis in these patients (Patte et al 2002).
In a large compassionate-use study, 245 patients (173 
children, 72 adults) with cancer who had or were at high risk 
for hyperuricemia were enrolled (Pui et al 2001a). Rasburi-
case 0.2 mg/kg per dose was administered for 1–7 days and 
could be given every 12 hours for the ﬁ  rst 72 hours in patients 
who were receiving chemotherapy and were at great risk of 
developing TLS. Hyperuricemia was deﬁ  ned as a uric acid 
concentration  6.4, 5.9, 6.4, 7.2, or 6.4 mg/dL in patients 
aged 0–2, 2–12, 12–14,  14 (males), or  14 (females) years, 
respectively. The most common diagnosis in the pediatric 
group was ALL (71%). AML (33%), NHL (26%), and ALL 
(18%) were the most frequent diagnoses in the adult group. 
Rasburicase was given to 117 pediatric and 49 adult patients 
as treatment for hyperuricemia; 56 pediatric and 23 adult 
patients received rasburicase as prophylaxis. There was a 
marked and constant decline in uric acid from a median of 
9.7 mg/dL (range 6.2–33.5) at diagnosis to a mean of 0.6 
mg/dL (range 0–8.1) after treatment in the pediatric group 
(p   0.001). Rasburicase produced a similar result in the adult 
group with a marked decline from a median of 11.9 mg/dL 
(range 7–24.3) at diagnosis to 0.7 mg/dL (range 0–5) after 
treatment (p   0.001). In the prophylaxis group, 79 patients Biologics: Targets & Therapy 2008:2(1) 138
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(56 children, 23 adults) had a signiﬁ  cant decline in uric acid 
levels. However, 10 patients required dialysis because of 
hyperphosphatemia, azotemia, or both. Four children and 
5 adults experienced mild adverse reactions that were drug 
related or of unknown etiology.
In a limited series of patients treated in 8 AIEOP 
(Associazione Italiana Ematologia Oncologia Pediatrica) 
centers from December 2002 to July 2003, we evaluated 
safety and efﬁ  cacy of rasburicase in treatment and pro-
phylaxis of hyperuricemia in children with malignancies 
at risk for developing TLS (Pession and Barbieri, 2005). 
We retrospectively reviewed 26 consecutive children: 
12 patients (46.2%), 8 BALL, 3 solid tumor, 1 NHL, 
had hyperuricemia (group 1, treatment group), whereas 
14 patients (54%), 7 NHL, 4 AML, 3 B-ALL had normal 
or moderately increased uric acid level (UAL) (group 2, 
prophylaxis group). Normal values were deﬁ  ned according 
age ( 5; 5–10;  10 years) and gender at onset. At presenta-
tion the mean UAL ± SD was 13.7 ± 3.4 mg/dL and 4.0 ± 
1.7 mg/dL for patients in group 1 and group 2, respectively. 
Other metabolic abnormalities present at baseline were: 
serum creatinine  1.3 mg/dL in 5 patients (19%) and serum 
phosphate  7.0 mg/dL in 3 (11%). Rasburicase was admin-
istered in 19 patients at the ﬁ  rst induction chemotherapy 
0–48 hours before the initiation of antiblastic infusion and 
in 7 during chemotherapy for relapse at 0.20 mg/kg IV 
daily for median duration of 4 days (1–11). All patients 
showed a signiﬁ  cant (p   0.001) reduction of UAL 48 h 
after treatment (group 1: 0.71 ± 0.64 mg/dL, group 2: 1.18 
± 1.14 mg/dL). Rasburicase produced a highly signiﬁ  cant 
(p   0.001) decrease in UAL within 24 hrs after the ﬁ  rst 
injection (group 1: 0.51 ± 0.39 mg/dL, group 2:1.83 ± 1.07 
mg/dL) with a response rate of 100% and 93% respectively. 
Normalization of creatinine and phosphorus levels was 
obtained after 5 and 4 days respectively the beginning of 
treatment. Only a child with Wilms’ tumor developed acute 
renal failure without requiring dialysis. Our experience 
conﬁ  rms that rasburicase is a safe and high effective drug, 
capable of inducing a rapid and marked decrease in UAL 
within 24 hours of the ﬁ  rst injection. Rasburicase was well 
tolerated in all patients. This would suggest its use (at the 
dosage of 0.20 mg/kg for at least 5 days) in children deﬁ  ned 
at high risk of TLS by clinical (ALL with leukemia/lym-
phoma syndrome, B-ALL FAB L3, stage III/IV NHL, bulky 
disease, renal impairment) or laboratory criteria (WBC   
50 × 109/L, LDH  2 times over normal range, UAL   7 
mg/dL, creatininemia or Ccr, cm × 0.55/creatinemia, over 
normal range for age). Patients at low risk would be treated 
with standard therapy (allopurinol, hyper-hydration, and 
urine alkalinization). The steady improvement of renal 
function during treatment with rasburicase in patients hav-
ing impaired renal function at presentation, none of whom 
required dialysis, is remarkable. The low incidence of ARF 
associated with the absence of toxicity suggests that this 
drug is cost-effective (Oldﬁ  eld and Perry 2006).
Prevention and therapy of TLS
All adult and pediatric patients with hematological malig-
nancy or solid tumors at risk of TLS deserve an adequate 
prophylaxis treatment; close monitoring of risk factors for a 
prompt identiﬁ  cation of signs and symptoms are important 
factors in preventing TLS-related life-threatening events. 
In this section we propose a possible therapeutic schema in 
adults and pediatric patient for prevention of TLS, according 
to risk group (Table 3) and for treatment of both for labora-
tory and clinical TLS (Table 4).
Regrettably, this approach may be unsuccessful in 
controlling severe hyperuri  cemia, and death as a result of 
TLS-related complications occurred in 1%–2% of the overall 
population.
Conclusions
TLS is a potential complication in any patient with malig-
nancies. It has been identiﬁ  ed in a population of patients at 
higher risk of TLS which includes subjects affected by bulky 
or highly chemotherapy-sensitive tumors such as hemato-
logical malignancies, whereas it is more rarely observed 
spontaneously or as a consequence of treatment in adult and 
pediatric solid tumors.
Hallmarks of TLS are hyperuricemia, hyperkalemia, 
hyperphosphatemia, and hypocalcemia which may follow 
the massive lysis of tumor cells. Major complications of 
TLS are metabolic acidosis and acute renal failure. In view 
of its complex pathophysiology and clinical presentation, the 
myriad of metabolic disorders must be assessed and treated 
rapidly. Proper ﬂ  uid management, careful alkalinization of 
the urine, correction of acidosis, inhibition of the formation 
of uric acid, or destruction of the already circulating uric acid 
molecules, as well as attention to the opportunity for starting 
antineoplastic treatments, are mainstays of therapy. Currently, 
allopurinol and rasburicase are the two drugs available for 
lowering serum uric acid. The advantages of rasburicase are 
its rapid onset thanks to its unique mechanism of action. It 
lowers pre-existing uric acid and prevents the further accu-
mulation of uric acid and xantyne, therefore minimizing the 
risk of tumor lysis syndrome and ARF, while allopurinol does Biologics: Targets & Therapy 2008:2(1) 139
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not lower pre-existing uric acid and has a delayed onset of 
action. On the other hand, rasburicase has no effect on the 
profound acid–base and electrolyte disturbances that can 
occur during TLS.
At the present time, rasburicase provides an alterna-
tive for the prevention of TLS in patients at high risk and 
it is strongly suggested for the treatment of hyperuricemia 
and TLS. This molecule should therefore be added to the 
formulary of hospital hematology and oncology clinics. How-
ever, there should be some restrictions for its use according 
to recommendations and guidelines to deﬁ  ne subgroups of 
patients that would beneﬁ  t from its use. Presently, there is a 
lack of pharmacoeconomic data comparing rasburicase and 
oral and/or intravenous allopurinol in the areas of delays 
in chemotherapy treatment and effects on renal function. 
Additionally, clinical data do not yet provide enough 
evidence to support replacing allopurinol with rasburicase 
as the standard of care in patients not at high risk of TLS or 
with laboratory TLS.
Moving towards more extensive and intensive 
antineoplastic strategies, both for children and elderly, the 
availability of a rapid and strongly effective drug such as 
Table 3 Prevention of tumor lysis syndrome
Pediatric patients
Low risk  - Allopurinol orally 300 mg/m2/day or 10 mg/kg/day 3 times.
  - However a single dose of rasburicase will be take into 
    account for also low-risk patients
  - Hyperhydratation with glucosaline or normal saline 
    solution 2.5–3 L/m2/day or 200 mL/kg/day if children  10 kg
  - Alkalinization NaHCO3 50–70 mEq/L to maintain urinary 
   pH    7
  - Furosemide if urine volume is  100 mL/m2/h or 3mL/kg/h 
   for  children   10 kg
High risk  - Rasburicase 0.2 mg/kg/day at least 4 hours before 
    beginning chemotherapy for 3–5 days
  - Hyperhydratation with glucosaline or normal saline 
    solution 2.5–3 L/m2/day or 200 mL/kg/day if children  10 kg
  - Furosemide if urine volume is  100 mL/m2/h or 
    3 mL/kg/h for children  10 kg
Adult patients
Low risk  - Allopurinol orally 300 mg/m2/day 3 times
  - Hyperhydratation 2.5–3 L/m2/day with glucosaline or 
    normal saline solution. Hydratation should always
     be performed, except in patients at risk of rapid volume 
overload
  - Alkalinization to maintain urine pH   7
  - Furosemide or mannitol if urine volume is  100 mL/m2/h. 
    Diuretics should be administered unless hypovolemia or
    obstructive uropathy are diagnosed to maintain urine  
    outputof at least 100 mL/m2/h with urinary speciﬁ  c 
   gravity   1010
High risk  - Rasburicase 0.05–0.2 mg/kg/day for 3–5 days
  - Hyperhydratation 2.5–3 L/m2/day with glucosaline or 
    normal saline solution. Hydratation should always be
    performed, except in patients at risk of rapid volume 
   overload
  - Furosemide or mannitol if urine volume is  100 mL/m2/h. 
    Diuretics should be administered unless hypovolemia or
    obstructive uropathy are diagnosed to maintain urine 
    output of at least 100 mL/m2/h with urinary speciﬁ  c
   gravity   1010
  - For solid tumors reduced chemotherapy schedule may 
    be evaluated to reduce tumor burden and related TLS risk
Rasburicase is contraindicated in patients with metahemoglobinemia, G6PD deﬁ  ciency 
or other metabolic disorders that may cause hemolitic anemia.
Table 4 Treatment of laboratory tumor lysis syndrome (LTLS 
and clinical tumor lysis syndrome (CTLS)
Laboratory TLS pediatric patients
Low risk  - Allopurinol orally 300 mg/m2/day or 10 mg/kg/day 3 times.
  - However a single dose of rasburicase will be take into 
    account for also low-risk patients
  - Hyperhydratation with glucosaline or normal saline solution
   2.5–3  L/m2/day or 200 mL/kg/day if children  10 kg
  - Urine alkalinization NaHCO3 50–70 mEq/L to
    maintain urinary pH   7
  - Furosemide if urine volume is  100 mL/m2/h or 
    3 mL/kg/h for children  10 kg
High risk - Rasburicase 0.2 mg/kg/day. at least 4 hours before
    beginning chemotherapy for 3–5 days
  - Hyperhydratation with glucosaline or normal saline 
    solution 2.5–3 L/m2/day or 200 mL/kg/day if 
   children   10 kg
  - Furosemide if urine volume is  100 mL/m2/h or 
    3 mL/kg/h for children  10 kg
Clinical TLS pediatric patients
-   Rasburicase 0.2 mg/kg/day at least 4 hours before beginning
chemotherapy for 3–5 days.
-   Hyperhydratation with glucosaline or normal saline solution 
2.5–3 L/m2/day or 200 mL/kg/day if children  10 kg.
-   Furosemide if urine volume is  100 mL/m2/h or 3 mL/kg/h for 
children  10 kg.
- Consider hemodialysis.
Laboratory and clinical TLS adult patients
There is no major differences in treatment of laboratory and 
clinical TLS in adult patients
- Rasburicase 0.2 mg/kg/day for 3–5 days.
-   Hyperhydratation 2.5–3 L/m2/day with glucosaline or normal saline 
solution. Hydratation should always be performed, except in patients at 
risk of rapid volume overload.
-   Furosemide or mannitol if urine volume is  100 mL/m2/h. Diuretics 
should be administered unless hypovolemia or obstructive uropathy 
are diagnosed to maintain urine output of at least 100 mL/m2/h with 
urinary speciﬁ  c gravity  1010.
- Low dose dopamine can be used to improve renal perfusion.
- Consider hemodialysis.
Rasburicase is contraindicated in patients with metahemoglobinemia, G6PD deﬁ  ciency 
or other metabolic disorders that may cause hemolitic anemia.Biologics: Targets & Therapy 2008:2(1) 140
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